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SUMMARY 
In this thesis, research results are reported on the role of dipalmitoyl phosphatidyl 
choline (DPPC) and DPPC-liposomes on the in vitro permeability characteristics of 
various antimycobacterial drugs across porcine bronchial tissue. The permeability 
flux values of the different compounds (isoniazid, ofloxacin and moxifloxacin) and 
their relevant DPPC formulations were determined using a continuous flow through 
perfusion system. Mean steady state flux values were compared statistically by 
means of a t-test at a significance level of 5% as well as an F-test using whole 
curve comparisons. The results indicated that the different formulations of drug and 
their DPPC combinations retard the permeation of drug through bronchial tissue. 
However, moxifloxacin permeation was significantly enhanced when in a DPPC-
liposomal formulation. These results demonstrate the important role that molecular 
weight, electrostatic charge, partitioning of the molecules in DPPC and DPPC-
liposomes play in transmembrane diffusion.  
In addition, the effect of individual drugs and their DPPC combinations on the 
surface tension lowering property of DPPC was evaluated. The results obtained 
showed minimal decreases in the surface tension lowering capability of DPPC; 
however, the minimal increases in surface tension do not alter the integrity of DPPC 
to a large extent.  
Drug susceptibility testing of Mycobacterium tuberculosis cultures against the 
individual antitubercular drugs and their DPPC combinations was done by using the 
Radiometric BACTEC 460TB™ system. Drug-entrapped DPPC liposomes were 
tested at concentrations comparable to their relative minimum inhibitory 
concentrations (MIC). The results for the BACTEC assay indicated that the 
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mycobacteria were susceptible to the developed drug entrapped liposomes; of 
which their encapsulation efficiencies for the relevant drugs were approximately ± 
50%. It was concluded that drug-entrapped DPPC liposomes could fulfill the dual 
role of pulmonary drug delivery and alveolar stabilization due to antiatelectatic 
effect of DPPC which can improve the distribution of anti-tubercular drugs in the 
lung. 
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OPSOMMING 
Hierdie tesis doen verslag oor navorsingsresultate met betrekking tot die rol van 
dipalmitoïel-fosfatidiel-cholien (DPPC) en DPPC-liposome in die in vitro-
permeasiekenmerke van verskeie antimikobakteriese middels oor vark- brongiale 
weefsel. Die permeasievloedwaardes van die verskillende verbindings (isoniasied, 
ofloksasien en moksifloksasien) en hul betrokke DPPC-formules is met behulp van 
’n deurlopende-deurvloei-perfusiestelsel bepaal. Gemiddelde vloedwaardes in ’n 
bestendige staat is statisties vergelyk met behulp van ’n t-toets op ’n 
beduidendheidsvlak van 5%, sowel as ’n F-toets met behulp van 
heelkurwevergelykings. Die resultate dui daarop dat die verskillende 
middelformules en hul DPPC-kombinasies middelpermeasie oor brongiale weefsel 
vertraag. Tog is die permeasie van moksifloksasien aansienlik versterk in ’n DPPC-
liposomale formule. Hierdie resultate bevestig die belangrike rol van molekulêre 
gewig, elektrostatiese lading, die verdeling van molekules in DPPC sowel as 
DPPC-liposome in transmembraandiffusie.  
Daarbenewens is die uitwerking van individuele middels en hul DPPC-kombinasies 
op die oppervlakspanningsverligtingsvermoë van DPPC beoordeel. Die resultate 
toon minimale afnames in die oppervlakspanningsverligtingsvermoë van DPPC. Die 
minimale toenames in oppervlakspanning het egter meestal geen 
noemenswaardige effek op die integriteit van DPPC gehad nie.  
Voorts is die vatbaarheid van Mycobacterium tuberculosis-kwekings vir die 
individuele anti-tuberkulêre middels en hul DPPC-kombinasies met behulp van die 
radiometriese BACTEC 460TB™-stelsel getoets. Middel-ingeslote DPPC-liposome 
is getoets in konsentrasies wat met hul relatiewe minimum inhibisiekonsentrasies 
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(MIK) vergelyk kan word. Die resultate van die BACTEC-toets toon dat die 
mikobakterieë vatbaar was vir die ontwikkelde middel-ingeslote liposome, met ’n 
enkapsuleringsdoeltreffendheid van ongeveer 50% vir die betrokke middels. Die 
studie kom tot die gevolgtrekking dat middel-ingeslote DPPC-liposome die dubbele 
rol van pulmonêre middel-lewering en alveolêre stabilisering kan vervul weens die 
anti-atelektatiese werking van DPPC, wat die verspreiding van anti-tuberkulêre 
middels in die long kan verbeter. 
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1. INTRODUCTION 
 
An increasing amount of research is focused on optimizing drug delivery as a 
method of improving pharmacotherapy. As oral administration is probably a non-
optimal delivery route for many therapeutic agents, growing attention is given to the 
potential of absorptive mucosae, including nasal, ocular, rectal, vaginal, buccal, 
sublingual and pulmonary tissue, as a non-invasive route of administration for 
systemic drug delivery. The pulmonary route seems most advantageous when 
taking into account that inhalation delivery may offer more rapid as well as a 
superior degree of drug absorption compared to that of other routes. However, with 
this route of administration, targeting a specific site of action requires the aid of a 
delivery vehicle that relies on the careful consideration of the drug to be delivered, 
as well as the unique properties of the tissue being targeted.1  
The human respiratory tract has the potential to provide means for non-invasive 
drug delivery as it is a highly specialised organ with a surface area of more than 75 
m2 of which the alveoli constitute about 95%. The good vascularisation, immense 
capacity for solute exchange and ultra-thinness of the epithelium are unique 
features that can facilitate systemic delivery of drugs. Controlling the manner in 
which drugs disperse, particle size and the consistency of the delivery have been 
researched extensively. Advances in these parameters have clearly made 
pulmonary delivery a practical approach for therapeutic agents. With more clinical 
data being made available in support of the efficacy and safety of inhalable drugs, 
pharmaceutical developers are recognizing that pulmonary delivery offers unique 
advantages. This delivery route has substantial impact on four areas of 
pharmaceutical development: proteins and peptides, fast-acting drugs, localized 
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lung infections and other pulmonary disease treatments (e.g. Mycobacterium 
tuberculosis).2 
Pneumonia and other lung infections such as tuberculosis (TB) remain a leading 
cause of death worldwide.2 A drug delivered by way of the pulmonary route can act 
directly at the infected site. It offers the potential for faster and more efficient 
therapy. This route also offers the reduced risk of drug resistance development as 
well as fewer side effects.2 Lung diseases such as asthma, emphysema or cancer 
can also expect similar treatment benefits with local treatments with drugs.3 
However, the permeability barrier of the lungs presents a major problem for most 
drugs when formulated without an absorption enhancer/promoter.4 To circumvent 
this problem, mixing of a pharmaceutically active agent with a pulmonary surfactant 
or a promoter have been tested for enhancing the systemic availability of drugs 
from the lungs. Many protease inhibitors, lipid or polymers have been tested for 
their efficacy in improving the systemic uptake of drugs from the lungs.4  
The mechanism of action by which surface–active agents manipulate the alveolar–
capillary transfer of solutes still needs to be elucidated. However, they are most 
likely to be involved in the increase in transcellular transport by way of an 
interaction and/or fluidisation of the cell membrane, a variation of tight junctions and 
an increase in paracellular permeability or a combination of both.4 
Surfactant uses in treatments beyond the traditional role of Surfactant Replacement 
Therapy (SRT) for neonates are currently being assessed.5 Some of the areas 
where surfactants are being utilised to improve drug delivery are being carried out 
in animal and clinical studies involving therapy of pneumonia.6  
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Exogenous surfactant’s particular spreading properties, ability to re-expand 
atelectatic areas in the lung and its ability to dissolve drugs that are insoluble in 
aqueous solutions suggests that it could be exploited to act as a pulmonary drug 
delivery agent. However, little is known about possible interactions between 
pulmonary surfactant and antimicrobial agents when combined.7 Furthermore, 
pulmonary surfactant also has the ability to form lamellar structures, i.e. liposomes.8 
Surfactant-based liposomal delivery system have shown great potential of being 
effective drug–delivery vehicles. The development of liposomal formulations for 
aerosol delivery with jet nebulizers has expanded the possibilities for effective 
utilization of aerosol based therapies in the treatment of pulmonary diseases.9  
Vesicle size is one of the critical components of liposome formulation for aerosol 
delivery as it determines site of impact. Liposomes impinging on the conducting 
airways will be cleared by mucocilliary action. However, when deposited in the 
alveolar region; liposomes will be subjected to different, slower clearance 
mechanisms.10 In addition; phospholipid vesicles have perceived advantages over 
other proposed drug carriers in the lung as demonstrated by the ability of Type-II 
cells to utilize administered phospholipids in the production of lung surfactant. The 
physiological as well as pathophysiological environment of the lung will also affect 
deposition and the utilisation of liposomes. Therefore further developments directed 
at liposome delivery to the lung are warranted.10 
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2.  LITERATURE REVIEW 
2.1 Epidemiology of Tuberculosis 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis (M.tb). It typically affects the lungs (pulmonary TB) but can affect other 
sites as well (extrapulmonary TB). There were an estimated 8.8 million incident 
cases of TB globally in 2010, 1.1 million deaths (range, 0.9 million – 1.2 million) 
among HIV-negative cases of TB and an additional 0.35 million deaths (range, 0.32 
million – 0.39 million) among people who were HIV-positive. Even though the 
incidence of TB has been falling since 2006, by an incidence rate of 1.3% per year 
(per 100 000 population) since 2002, it still remains one of the leading causes of 
preventable deaths in more than 198 countries including South Africa.11 
By making use of modern day DNA extraction and purification methods, molecular 
evidence for TB was found in an ancient Egyptian mummy from the New Kingdom 
which dated back to about 1550 — 1080 BC.12 The molecular diagnosis of 
tuberculosis in historic specimens has thus far only been successful in a Peruvian 
mummy dating to about 1000 — 1300 AD.13 Robert Koch, a German physician, was 
the first to identify and describe M.TB bacilli in 1882 where tuberculosis was 
generally referred to as “consumption” in the poor urban population in Britain and 
Europe in the early 19th century.14 The only treatment available was to stimulate the 
body’s own immune system by focusing on a healthy diet, fresh air, hygiene and 
the administration of expectorants and purgatives. This led to the opening of the 
first sanatorium in 1854 in Germany.15 The nature of this treatment plan proved 
success compared to any previous treatment regimens and a further critical 
improvement of public health led to the reduction of tuberculosis cases before the 
discovery of streptomycin in the mid-20th century.  
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As indicated in the global tuberculosis control report of 2011 from the World Health 
Organisation 10, South Arica currently has one of the highest incidence rates of TB 
per 100 000 people ( >300) which is illustrated in Fig. 1.16 
 
Figure 1: World map indicating the incidence of TB for 2010.
16
 
2.2 Multidrug – and Extensively drug - resistant tuberculosis 
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant 
tuberculosis (XDR-TB) occurs when the M.tb strain presents resistance to, at least 
isoniazid (INH) and rifampicin (RIF). In the case of XDR-TB it is compounded by the 
additional resistance to the second line drugs which can be any of the 
fluoroquinolones as well as at least one of the injectable drugs kanamycin, 
capreomycin or amikacin. This is a growing public health and clinical problem 
worldwide as well as a great concern in South Africa especially pertaining to 
individuals co-infected with HIV/AIDS.17,18 
It is estimated that the 450,000 multidrug-resistant (MDR) TB cases that occur 
globally constitute 14% of the global burden of TB. Which is more, South Africa 
contributes approximately 1-2% to this 14% MDR-TB occurrence.17,19 Concern over 
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MDR/XDR TB was extrapolated when, in 2006, an MDR/XDR TB outbreak involved 
536 TB patients at the Church of Scotland Hospital in KwaZulu-Natal South Africa; 
221 were found to have MDR-TB of which 53 were diagnosed with XDR-TB. Within 
25 days, 52 patients died. This outbreak also involved a high proportion of HIV co-
infection which was confirmed by 44 of the 53 patients who were found to be HIV 
positive. It was thought at the time that the co-infection with HIV led to the 
development of XDR-TB. However, at the 2nd TB conference in Durban (2010), it 
was indicated that it primarily originated through inadequate infection control. 
Patients who, with no prior TB or HIV infection, were hospitalised for other ailments 
contracted XDR- TB through inadequate infection control.20  
2.3 Current TB Chemotherapy 
Streptomycin was discovered in 1944 and only then did the treatment of TB 
become possible. This was then followed by the introduction of isoniazid (INH) in 
the 1950s which established the basis of anti-TB chemotherapy until the 1960s. 
Streptomycin (STM), INH and para-aminosalicylic acid (PAS) comprised the anti-TB 
drug regimen in the initial months during that period. This was followed by INH and 
PAS in succeeding months, resulting thus in a total duration of administration of 18 
months. In 1965, rifampicin (RIF) was discovered and in the 1970s, a short-course 
treatment for TB was launched. The directly observed treatment, short-course 
(DOTS) strategy, when properly implemented with the necessary infrastructure, 
produces high TB cure rates and curtails the development of acquired drug-
resistant TB.21 
According to the South African tuberculosis control programme, the current 
standard first line treatment regimen of 2004 consists out of an initial (or intensive) 
phase of 2 months consisting of 4 drugs INH, RIF, pyrazinamide (PZA), and 
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ethambutol (ETH). To ensure complete elimination of mycobacteria, 4 months of 
INH and RIF continued treatment is followed after the intensive phase (Table 1).22,23 
Pre- 
Treatment 
body weight 
Intensive phase: 2 months Continuation phase: 4 months 
RHZA 
150 / 75 / 400 / 275 mg 
RH 
150 / 75 mg 
RH 
300 / 150 mg 
30 – 37 kg 2 tablets 2 tablets - 
38 – 54 kg 3 tablets 3 tablets - 
55 – 70 kg 4 tablets - 2 tablets 
≥ 71 kg 5 tablets - 2 tablets 
R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol 
Table 1: Treatment regimen for known drug sensitive TB.
22 
Although treatment of drug-susceptible TB under ideal conditions by DOTS may be 
successful in 95% of cases, cure rates in the ﬁeld are often signiﬁcantly lower.24 
However, the reality of the DOTS strategy has revealed that it is difficult to maintain 
in many national TB control programmes, especially over a long time. One specific 
example is the failure to ensure patient compliance. One of the most common 
reasons for patient non–compliance is due to the treatment associated adverse– 
effects. First line drugs have been known to cause nausea, vomiting and drug 
induced hepatitis. Non-compliance to the recommended chemotherapeutic regimen 
not only lowers cure rates, but leads to the development of drug-resistant TB, 
inclusive of the formidable scenarios of MDR-TB and XDR-TB.25,26 Where 
moxifloxacin, a second line drug used in the treatment of MDR-TB, has been 
associated with gastrointestinal disturbances and neurological dysfunction.27 
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Most of the standard chemotherapy has proven to be ineffective for patients that 
have MDR-TB and although there is no cure for XDR-TB, a standardised regimen is 
under review.22 Drug resistance is predominantly detected in patients who have 
previously been treated for TB. This could be due to the previously mentioned 
failure to comply with the extensive drug regimens resulting in the pathogens 
becoming resistant to the first line drugs, namely INH and RIF.25-27,28,29 There are 
two treatment possibilities when faced with MDR-TB.  Firstly, a combined treatment 
plan of aminoglycoside, a ﬂuoroquinolone, PZA, and ethionamide or prothionamide 
can be used for MDR-TB with resistance to both INH and RIF. However, the 
second option of an aminoglycoside, ﬂuoroquinolone, PAS, cycloserine, and 
ethionamide or prothionamide is required for disease with resistance to INH, RIF, 
ETH and PZA (Table 2).21,22 
 
Intensive phase: 6 months or at least 4 months 
Drug 
Body Weight 
< 33 kg 33 – 50 kg 51 – 70 kg ˃ 70 kg 
Kanamycin
# 
15 – 20 mg/kg 500-750 mg 1000 mg 1000 mg 
Pyrazinamide 30 – 40 mg/kg 1000 - 1750 mg 1750 - 2000mg 2000 - 2500 mg 
Ethionamide 15 – 20 mg/kg 500 mg 750 mg 750 - 1000 mg 
Ofloxacin
¥
 800 mg 800 mg 800 mg 800 - 1000 mg 
Or     
Levofloxacin 7.5 – 10 mg/kg 750 mg 750 mg 750 - 1000mg 
Or     
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Moxifloxacin 7.5 – 10 mg/kg 400 mg 400 mg 400 mg 
Terizidone
ϕ
 15 – 20 mg/kg 750 mg 750 mg 1000 mg 
Or     
Cycloserine 155 – 20 mg/kg 500 mg 750 mg 750 - 1000 mg 
     
 
Continuation phase: 18 months 
Drug 
Body Weight 
< 33 kg 33 – 50 kg 51 – 70 kg ˃ 70 kg 
Ethionamide 15 – 20 mg/kg 500 mg 750 mg 750 - 1000 mg 
Ofloxacin
¥
 800 mg/kg 800 mg/kg 800 mg/kg 800 - 1000 mg 
Or     
Levofloxacin 7.5 – 10 mg/kg 750 mg 750 mg 750 - 1000 mg 
Or     
Moxifloxacin 7.5 – 10 mg/kg 400 mg 400 mg 400 mg 
Terizidone
ϕ
 15 – 20 mg/kg 750 mg 750 mg 1000 mg 
Or     
Cycloserine 15 – 20 mg/kg 500 mg 750 mg 750 - 1000 mg 
Table 2: Treatment regimen for MDR - TB.
 # 
Kanamycin may be substituted with amikacin; 
¥
 
Moxifloxacin (patients ˃ 8 yrs) or levofloxacin (patients < 8 yrs); 
ϕ
 Pyridoxine (Vit B6) 150 mg to be 
given daily to patients on terizidone or cycloserine.
22 
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Another characteristic of TB that makes treatment difficult besides prolonged 
treatment and acquired resistance (genetic resistance) is its persistence. M.tb can 
persist within the human host for years without causing disease, in a syndrome 
known as latent tuberculosis.30,31 Mycobacteria are obligate aerobes however, they 
have been known to encounter hypoxic environments. This leads to the suggestion 
that the development of physiological resistance could possibly play a role in latent 
infection. Wayne and co-worker demonstrated that the bacillus, when oxygen is 
steadily depleted, terminates growth and develops into a defined non-
replicating/dormant form; however, when oxygen is completely removed from the 
environment, the bacilli cannot survive.32 These latent/dormant mycobacteria are 
able to survive within granulomatous lesions within the lungs that are surrounded 
by foamy macrophages.33 As the current chemotherapy only works for growing, 
drug susceptible TB, the lengthy treatment time depends on the presence of 
dormant bacteria present in the old lesions that become active again.34 Evidently, 
this model is a commonly accepted paradigm that still remains to be proven. 
However, if it turns out that this idea is a true reflection of aspects in vivo, the 
development of drugs that specifically target dormant bacilli could have a profound 
impact on tuberculosis therapy. The administration of conventional drugs along with 
the potential ‘anti-dormancy’ drugs might shorten the treatment duration as well as 
treatment efficacy regarding latent infection. 33, 34  
Patients who are co-infected with HIV present some major challenges when it 
comes to TB treatment. Firstly, drug-drug interactions between anti-retroviral drugs 
(ARVs) are included. RIF interactions with protease inhibitors and non- nucleoside 
reverse transcriptase inhibitors lead to decreased concentrations of ARVs, thus 
resulting in the loss of antiviral efficacy and the development of viral resistance. The 
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second complication for HIV-infected patients receiving TB treatment is drug 
toxicity. For example, a retrospective study done by Yee et al which involved 
patients treated for TB in Canada found that HIV co-infected patients were 3.8 
times more likely to experience a significant drug-related adverse event.35 
Therefore, these overlapping toxicities may lead to treatment discontinuation, 
increasing the probabilities of nonadherence and drug-resistance. Thirdly, an 
immunopathological reaction, which is also termed “the immune reconstitution 
inflammatory syndrome” (IRIS), occurs most frequently when antiretroviral therapy 
is resumed in patients with tuberculosis.23,30,36,37 
Improvements for new TB treatments will require the fulfilment of three major 
objectives. Firstly, to discover new chemotherapies that decreases the duration of 
treatment due to faster-acting drugs. Secondly, to develop novel antimycobacterials 
which can combat the emergence of MDR-TB and thirdly, to target dormant bacilli 
to treat latent TB infections as previously discussed.37  
2.4 Prospects and Challenges for Future TB Chemotherapy 
Besides the recent discovery of a diarylquinoline TMC207 (Bedaquiline) which has 
proven to be promising drug candidate for the treatment of TB; the past 30 years 
has left a crucial gap in drug development. This new drug incorporates a novel 
approach by binding to a new target, the mycobacterial ATP synthase.38,39 The 
reason for this crucial gap in drug discovery is due to two kinds of obstacles. Firstly, 
the “scientific obstacles” or so-called “biological uncertainties” about M.tb is 
currently under debate. As previously mentioned, a universal understanding of the 
heterogenetic characteristic of TB lesions in patients is still sought. Likewise, 
understanding the critical mechanisms that underlie the survival of M.tb during the 
long periods of chemotherapy is not completely understood. Therefore, these gaps 
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in the knowledge of M.tb biology are making the identification and validation of 
potential targets relevant within the human host very difficult.40,41 These 
uncertainties are also the reason why pharmaceutical companies are reluctant to 
invest in anti-TB drug development as it presents varied risks for their businesses. 
This results in the lack of funding for academic laboratories to run research projects 
that connect basic and applied science. I mention this for the specific reason that if 
faster progress is to be made with drug discovery for TB; then advanced knowledge 
of M.tb’s metabolism, physiology and genetics need to be interpreted into the 
identification of new compounds and targets.41 Currently, there is a lack of 
adequate animal models available that are able to accurately predict the required 
treatment duration with newly identiﬁed compounds. In this regard, the guinea pig 
model is currently explored as an alternative for the mouse model since it 
resembles TB pathology in humans more closely. 42 
It was stated by McKinney that “ In the TB field, target identification and target 
validation projects are not carried out by biotech or pharmaceutical companies due 
to lack of interest and lack of expertise – there is little capacity and expertise on TB 
among pharmaceutical companies since there have not been on-going TB 
development projects. If this work cannot be done by academic laboratories, the 
process gets stuck”.43 There is the need to enable the academic sector to go 
beyond the proof of principle that traditionally is the final aim and it is necessary to 
re-think the traditional roles played by academia and pharmaceutical industry in the 
drug discovery and development.43,44 
One prospect that has shown some promise in the advancement of TB 
chemotherapy is the repurposing of current chemotherapeutic agents.45 Revising 
current drugs and reconstituting drug combinations have indeed improved 
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treatment outcomes. One such an example is a recent study done at Stellenbosch 
University, called NC001. It involved a new drug combination of an experimental 
medicine called PA-824 (nitroimidazole derivative) alongside bedaquiline, 
moxifloxacin and pyrazinamide. This cocktail which was dubbed PaMZ, proved to 
be safe and presented the potential to reduce the time needed to treat drug-
resistant forms of the disease.46,47 The study holds importance from a drug 
development perspective as it was using a novel approach. Another such case 
involved linezolid in the treatment regime and it achieved great success in patients 
with uncomplicated drug-resistant TB and for previously treated patients with XDR-
TB.48 However, a concern which one would need to take into consideration when 
including new derivatives in different drug combinations is the possibility of cross-
resistance. 44  
Currently, a common belief to approach the investigation of drug treatment efficacy 
for tuberculosis lies in exploring novel systems for drug delivery.43 One such an 
innovative approach was investigated during the course of this thesis where the 
feasibility of using phospholipid structured liposomes in drug delivery in vitro was 
investigated. 
2.5 Liposomes as drug-delivery vehicles: Application and prospects 
New approaches and new ways of thinking for TB drugs treatment are not only 
becoming necessary to fight this disease but essential; especially when it comes to 
patients with co-infections and drug resistance. As it stands, Sosnik et al stated that 
“nanotechnologies appear as one of the most promising approaches for the 
development of more effective and compliant medicines”.28  
Liposomes can be micro to nano–sized vesicles that consists of a phospholipid 
bilayer surrounding an aqueous core. The aqueous centre allows for the 
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encapsulation of hydroliphic drugs whereas the hydrophobic character of the 
membrane can entrap insoluble drugs.49 
Academia has contributed more than industry regarding relevant research involving 
liposomes as drug carriers. One such example is the development of sterically–
stabilized liposomes (SSL). This led to the combined efforts to develop SSL and 
their efficient remote loading with the drug doxorubicin (DOX) resulting in the 
development of DOXIL® (approved in the US since 1995).50 
There have been other liposome - and liposome-like-based pharmaceutical 
products, intravenously injectables, approved by the US FDA such as 
DaunoXome®, Ableet®, Amphotech® and AmbiSome®. 50 This is evidence that there 
is potential for liposome technology to mature in sophisticated pharmaceutical 
products. However, the high cost of lipid raw materials used for liposome 
preparations still plays a crucial role in slowing down the development process of 
such products. 
The main purpose of using liposomes as drug carriers is to achieve selective 
localisation of an active drug in the infected sites. This is where liposomes differ 
from other controlled release systems with various carriers as drug release can 
occur either in plasma or at the site of administration. For this form of therapy to be 
proven effective, the encapsulated drug in appropriate dosage should be made 
available to the target cells.50 Passive or active targeting can be used to obtain 
selective localisation. When the physical properties of the liposome and the 
microanatomy of the target tissue determine drug selective localisation, passive 
targeting is obtained; whilst active targeting requires an antibody or ligand attached 
to the liposome’s surface. This has the ability to act as a ‘homing-devise’ so that the 
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liposome can recognise the diseased cells in addition to reaching the disease 
site.50,51,52 
Oh et al investigated the formulation of the antibiotics ciprofloxacin and 
azithromycin in liposomes and tested their antibacterial activities in vitro against M. 
avium using a conventional passive-entrapment as well as targeting of the 
reticuloendothelial system.53 Both drugs showed enhanced antimycobacterial effect 
in liposomes. Similar results were obtained with different liposome-entrapped 
second-line antibiotics.54 Another illustration of liposomes with enhanced affinity 
towards lung tissue was reported by Deol and co-worker for the development of 
more effective chemotherapy against TB.55 
2.6 Local delivery of anti-TB drugs to the lung: Implications of Surfactant as a 
carrier 
Local delivery to the lungs by inhalation has emerged as one of the most attractive 
administration routes to target pulmonary TB infection. Inhaled therapy directly 
delivers the drug to the diseased organ with a reduction in adverse effects 
associated with systemic toxicity.56 The manipulation of particle characteristics 
including size, surface chemistry, surface charge, and surface area, allows for the 
possibility of synthesising particles speciﬁc for targeting to various cellular 
populations and organs including the respiratory tract.57,58 In this context, different 
industrial technologies such as employing a spray drying technique to produce 
nanoparticles made of either natural (e.g. gelatin) or synthetic (e.g. 
polybutylcyanoacrylate) polymers are investigated.59 These overviews display some 
of the nano-carriers explored for the local administration of anti-TB drugs.28  
The use of exogenous surfactant as a drug delivery agent has shown immense 
potential in this regard. Pulmonary surfactant comprises of a complex mixture of 
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lipids (approximately 80-90%) and several specific surfactant proteins (10%, 
surfactant protein A, B, C and D) rendering it with unique spreading properties and 
dynamic surface tension behaviour. These characteristics portend to the ideal 
carrier of choice to instil therapeutic agents into the lung; holding to the theme, 
specifically antimycobacterial drugs. Besides mechanical stabilisation of lung 
alveoli, surfactant also transports mucus and inhaled particles, protects against 
lung oedema and can also act as a local defence against infection by aiding the 
defence properties of alveolar macrophages.60  
In the advanced stages of pulmonary TB, patients develop pulmonary surfactant 
dysfunction resulting in alveolar collapse and respiratory distress. The M.tb bacteria 
reside in the alveoli and are in close proximity with the alveolar surfactant. Chimote 
et al proposed that the mycolic acid found within the bacteria’s cell wall interact with 
the surfactant causing this dysfunction.61,62 Furthermore, ﬁndings from Wang et al 
documented that TB contains multiple lipids that can directly impair the biophysical 
function of endogenous and exogenous pulmonary surfactants.63  
Russia initially investigated pulmonary drug delivery in TB. They addressed issues 
ranging across drug selection, aerosol generation, clinical outcome and adverse 
effects. However, this literature is not readily available.64-70 One such a particular 
study of interest was done by Lovacheva et al.71 They demonstrated that a 
collective dose of 700 mg of a surfactant designated as “Surfactant-BL” over 4 
weeks in 70 patients resulted in significantly decreased sputum counts in 70% of 
cases, complete sputum conversion in 83% in 2 months, and highly improved 
resolution of lesions.71 The reasoning behind the efficacy of surfactant therapy in 
pulmonary TB infection was elucidated by Stoops et al.72 These authors explained 
that bacteria are surrounded by a thick lipid coat primarily consisting of trehalose 
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dimycolate (TDM). This extensive coat shields the bacterium from the immune 
system's response and antibiotics. However, their studies revealed that exposing 
bacteria to certain surfactants enhanced the effectiveness of antibiotics and the 
immune system’s response by disrupting the protective barrier (Fig. 2).72  
 
 
 
Figure 2: A bacterium which maintained a more extensive TDM coat (white) which has been 
partially dislodged in exposure to surfactant but remarkably maintains the bacterium's 
shape. This image illustrates the rigidity of the TDM outer layer.
72 
 
The innovative use of lipid surfactants offer two possible advantages. Lipids such 
as dipalmitoylphosphatidylcholine (DPPC), which comprises ± 90% of pulmonary 
surfactant, can be used to formulate drug-carrying liposomes due to the general 
spreading effects and the ability to form lamellar structures.73 In addition to regional 
drug delivery, with the increased atelectasis and lung damage associated with 
advanced TB, exogenous surfactant can act as a replacement therapy to re-expand 
the atelectatic areas (restore alveolar stability) which are most likely to be infected 
areas (Refer back to dormant bacilli previously discussed).74,75 
The progress of nanotechnology in developing inhalable nanoparticle encapsulated 
antitubercular drugs and drug-encapsulated liposomes, as previously discussed, 
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are currently being investigated for improving drug delivery and decreasing the 
associated side-effects.76,77 Zaru et al prepared drug-loaded freeze-dried 
liposomes, designed for the investigation of delivery to the lungs after rehydration.78 
They proposed that the interactions between the drug and membrane components 
(assembly, rigidity and integrity of the liposome membrane) should be taken into 
consideration when designing liposomal formulations intended for pulmonary 
delivery.78  
Likewise, for the administration of drugs that are intended to act topically in the 
lungs, direct deposition to the lungs by some type of aerosol delivery technology 
needs to be taken into account when developing drug-loaded liposomes.79 Previous 
studies have found that the lipid composition preparation and size could be a large 
determinant of its ability to be nebulized. More so, the shear forces experienced in 
the nebulizers may result in liposome damage and the effect of the droplet 
impact.80-84 
2.7 Pulmonary Mucosa and Drug delivery 
As pulmonary drug delivery receives acknowledgment, the need for validated test 
systems, methods and guidelines for regulatory purposes has become greater. 
Therefore the first step in drug profiling for delivery via the respiratory tract needs to 
address intrinsic physicochemical parameters and their impact on or correlation 
with absorption and solubility as well as taking into consideration the specific 
biology of the lung.85 The respiratory tract is a highly specialised organ with a 
surface area of more than 75m2 and can be divided into two areas: the upper 
conducting airway and the lower respiratory regions. The conducting region 
consists of the nose, nasal passages, mouth, pharynx, oesophagus, larynx and 
trachea. The respiratory region consists of bronchi and alveoli.86 
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The solubility and lipophilicity of drugs may affect their behaviour in the bronchial 
and deep lung spaces (e.g. whether they reside for long periods in the respiratory 
system versus fast permeation across epithelial cell barriers). In addition, the 
properties of inhaled aerosolised drug particles such as size, shape, density, 
hygroscopicity, velocity and pressure of delivery, and charge should be taken into 
consideration. Moreover, the physiological state of the respiratory tract will also 
have an impact on the correct point of delivery inside the respiratory tract (upper 
airways versus deep lung).87   
Solubility, pKa, protein binding, polar surface area, and charge or rotatable bonds 
are also important properties of drugs that will influence their permeability across 
the lung epithelial barrier. It should also be taken into account that mucus and 
surfactant might influence solubility and permeability characteristics of a given 
drug.85 
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Figure 3: Comparison of the upper airways and the deep lung. Differences are found in the 
absorption area, cellular variety and height, lining composition (mucus vs. surfactant), 
thickness, and total volume. 
85 
 
Figure 4: A; Cross section through a bronchiole in lung. B; The bronchial wall is lined by 
pseudostratified ciliated columnar epithelium with goblet cells.
88,89
 
A B 
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2.8 Transmembrane diffusion processes 
The manner in which substances diffuse through liquids, solids, and membranes is 
a process of great importance when considering drug delivery. The transmembrane 
diffusion process is passive and requires only a concentration differential as the 
driving force. In this manner, a molecule must first diffuse through the vehicle in 
which it is contained to the membrane interface and then partition from the vehicle 
into the upper lamina of the membrane. Molecules will then diffuse within the 
membrane, equilibrating laterally and reach steady state conditions, from the distal 
surface of the medium. It is also possible that there could be extensive adsorptive 
interactions resulting in the formation of a “reservoir”. Finally the molecule partitions 
either to the adjacent membrane strata or into the receptor fluid (under the 
influence of the concentration gradient). Adsorption may occur once again. In this 
manner, diffusion through any one of the layers or any of the partitioning events 
may control the overall rate of permeation.90,91 
Diffusion across mucosa can take place along two pathways i.e. transcellular 
(passage across cells) and paracellular or intercellular (passage between cells). 
Transcellular diffusion may occur through the use of a receptor mediated binding 
followed by vesicular transport (transcytosis) or independently by means of passive, 
absorptive transcytosis (fluid phase). Paracellular diffusion is commonly thought to 
occur by means of tight junctions between two or three cells. Another classification 
of diffusion processes is into polar (aqueous channels in mucosa) and non-polar 
(partitioning into the lipid bilayer of the mucosa) pathways. It would seem that the 
passage of most molecules across the mucosa appears to be a simple first-order 
diffusion process (Fig. 5).91,92 
Stellenbosch University http://scholar.sun.ac.za
 22 
 
 
Figure 5: The main routes for transepithelial absorption are the transcellular passive 
diffusion and transcytosis, a transcellular route involving transport by vesicles, the 
transporter-mediated transport for small peptides, and the paracellular passive transport 
through tight junctions.
93 
As previously discussed, the physio-chemical properties of a drug such as partition 
coefficient, molecular weight, solubility, ionisation, and chemical nature will 
influence/determine its diffusion through any tissue membrane. On the other hand, 
the partitioning coefficient of the drug is the governing factor for which pathway it 
will follow during diffusion through the membrane. Hydrophillic molecules are 
expected to permeate predominantly via the intracellular route whereas lipophilic 
molecules are expected to permeate predominantly by means of the intercellular 
lipid domains.94 A mixed permeation model has been proposed where drugs diffuse 
through tissue predominately by way of continuous intercellular lipid domains. 
According to this model, lipid and polar regions of the membrane could provide the 
micro-routes through which the permeant diffuses, depending on its partition 
coefficient.94 On the other hand, surfactant molecules may enhance or retard 
partitioning by reducing the surface tension between the carrier vehicle and the 
membrane surface, but may also disrupt the barrier layers of the membrane.95  
Basolateral Side 
Apical Side 
Transcellular Paracellular passive 
via tight junctions 
Via a 
Transporter 
via transcytotic 
vesicles 
passive 
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2.9 Aim 
Therefore the aim of my study was: 
i) To determine the diffusion kinetics of two different classes of 
chemotherapeutic drugs used in TB treatment (Isoniazid, Ofloxacin and 
Moxifloxacin) through porcine bronchial tissue and the role of DPPC on their 
permeability (paying specific attention to liposomal preparation as drug carriers).  
ii)  To evaluate the effect of individual drugs and their combinations on the 
surface tension lowering property of dipalmitoyl phosphatidyl choline (DPPC) as 
well as encapsulation efficiency of the drug-loaded liposomes.  
iii) To investigate drug susceptibility of Mycobacterium tuberculosis cultures 
against the individual antibiotics and their DPPC combinations by using the 
Radiometric BACTEC 460TB™ system 
 
3. MATERIALS 
1,2 Dipalmitoyl-L-α-phosphatidylcholine (DPPC) was purchased from Avanti polar 
Lipids Inc. Isoniazid (INH), Ofloxacin (Oflox) and Moxifloxacin (Moxi) used for the 
permeability studies as well as BACTEC 460™ experiments were purchased from 
the Sigma Chemical Company. (St. Louis MO, USA). Chloroform used was HPLC 
grade. All other chemicals used were of the highest analytical grade. Sterile water 
for injection was used in the BACTEC 460™ studies.  
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CHEMICAL STRUCTURES OF ANTITUBERCULAR DRUGS 
Isoniazid  C6H7N3O 
               
Mw = 137.139 g/mol 
Ofloxacin  C18H20FN3O4 
  
Mw = 361.38 g/mol 
Moxifloxacin C21H24FN3O4
 
Mw = 401.431 g/mol 
Figure 6: Chemical structures of Antimycobacterial drugs 
 
4. METHODS 
 4.1 Liposomal Preparations 
The antitubercular drug-loaded liposomes were prepared by a modified thin-film 
hydration method maintaining the drug to DPPC at a 1:1 w/w ratio. The final 
concentration of DPPC and drug was kept at 2.5 mg/ml.  
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4.1.1 Drug Loaded liposomes 
Thin Film Formation 
The drug:lipid ratio was maintained at 1:1 ration w/w. Therefore, for every milligram 
of DPPC used for liposomes, a milligram of drug was added to the hydrating 
medium. DPPC was dissolved in a 2:1 chloroform: ethanol mixture, after which the 
organic solvent was removed at a temperature of 38ºC by vacuum rotary 
evaporation (Heidolph LABOROTA 4003). A homogenous thin lipid film was 
deposited during the evaporation of the solvent. The round bottom flasks were then 
kept in a vacuum pump dryer (Townson & Mercer Ltd) overnight. DPPC  
Film Hydration 
The individual drugs at a ratio of 1:1 by weight to DPPC were singularly dissolved in 
heated phosphate buffered saline (PBS pH 7.4) at 45ºC. The resulting dried lipid 
layers were then hydrated with this aqueous solution of PBS (pH 7.4) and drug 
combination. Small glass beads were added to the flask which was gently agitated 
for 30 min in a water bath at 45ºC until a homogenous suspension was formed. The 
suspension was kept at 4ºC overnight after being sealed under a N2 atmosphere to 
prevent oxidation and ensure proper hydration of the lipids. 
 
4.1.2 Size Reduction and Homogenisation of Liposomes  
Ultra sonication 
The liposomal suspension of Multi-Lamellar Vesicles (MLV) was heated to a 
temperature of 37ºC prior to further studies and placed in the middle of an ultra-
sonication bath (Bransonic 220) and exposed to ultrasonic pulses for 3 min in total 
in 15 sec intervals whilst agitating the flask gently. 
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Extrusion 
The ultra-sonicated liposomal drug suspension was filtered-extruded through a 
polycarbonate membrane filter using the LiposoFast-Basic™ extruder consisting of 
Teflon Luer lock type Hammilton syringes (Avestin, Inc Canada). A maximum 
volume of 500 μl, at a time, was passed through eleven times, back and forth, 
through the 100 μm filter whilst the temperature was kept close to 45ºC.96  
Optical Microscopy 
To confirm the formation of liposomes, samples of the MLVs suspension as well as 
the extruded suspension were observed on an Olympus Cell^R system attached to 
an IX-81 inverted fluorescence microscope equipped with an F-view-II cooled CCD 
camera (Soft Imaging Systems). Images were acquired by using an Olympus Plan 
Apo N 60x/1.4 Oil objective and the Cell^R imaging software.  
4.2 Tissue preparation 
Fresh porcine bronchial tissue was obtained from Winelands Pork Abattoir.  The 
tissue specimens were immediately transported on ice to the laboratory within 1 h. 
Excess connective and adipose tissue were trimmed away and tissue specimens 
were snapped frozen in liquid nitrogen and stored at -80ºC. No specimens were 
included in the study where there was any evidence of disease that might influence 
the permeability characteristics of the tissue. The Ethics committee of the 
Stellenbosch University granted approval for this study.  
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4.3 Permeability experiments 
The diffusion kinetics of antituberculosis drugs (alone or as DPPC suspensions or 
as filtered-extruded liposomes) through porcine lung tissue was determined with a 
flow-through diffusion system (ISCO Retriever IV) (Fig 7).  
 
Figure 7: Flow-through diffusion apparatus used in the present study 
 
Bronchial tissue specimens were equilibrated for approximately 10 min at room 
temperature in phosphate-buffered saline (PBS, pH 7.4) before each permeability 
experiment. The specimens were then cut very carefully, as not to damage the 
epithelial surfaces, into 4 mm2 sections. The individual sections were mounted in 
the flow-through diffusion cells (exposed area 0.039 cm2). Permeation studies were 
performed on 7 tissue replicates for each experiment. Tissue disks were 
equilibrated for 10 min with PBS (pH 7.4) at 36.5ºC in both the donor and acceptor 
chambers of the diffusion cells. After equilibration, PBS was removed from the 
donor chamber and replaced with 0.5 ml of antimycobacterial drug and 
DPPC/DPPC-liposomes concentrations as described above. PBS at 36.5ºC was 
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pumped through the receiving chambers at a rate of 1.5 ml/h (IPC High Precision 
Multichanger Dispenser ISMIATIC) and collected, by means of a fraction collector, 
at 2 h intervals for 24 h. The permeability studies were performed under sink 
conditions, i.e. at the completion of each run the concentration of permeant, in this 
case antituberculosis drugs, never reached 10% of that in the donor chamber.97  
 
4.4 HPLC detection of drugs 
Permeant containing effluent samples, collected from the acceptor compartments of 
the perfusion apparatus over the 2 – 24 h sampling intervals, were analysed using 
a Hewlett Packard 1100 series high–performance binary liquid chromatograph fitted 
with a diode-array UV detector (Agilent Technologies, Waldbron, Germany). The 
analytical parameters are summarised in Table 3. 
4.5 Calculation of flux values 
Flux values (J) of antimycobacterial drugs across bronchial tissue were calculated 
by means of the relationship: J = dQ/dt x 1/A ng x cm-2 x min-1), where Q = 
quantity of substance crossing membrane (ng), A = membrane area exposed (in 
cm2), and t = time of exposure (in min).   
4.6 Steady-state kinetics 
Reaching of steady state (equilibrium kinetics) was assumed to have been reached 
for a particular drug compound, when no statistically significant differences (p<0.05) 
(ANOVA and Duncan’s multiple range test) between flux values were obtained over 
at least two consecutive time intervals.  
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4.7 Statistical analyses 
Non-linear regression analyses (third order polynomial) using GraphPad Prism, 
Version 5 (GradPad Software Inc, San Diego, CA, 92130 USA) were performed.98 
A F-test was used to compare entire curves. An unpaired t test with Welch’s 
correction was used to investigate possible differences between flux means of 
bronchial membranes at 2 h intervals. A significance level of P<0.05 was used for 
all tests and comparisons. 
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Parameter Isoniazid Ofloxacin Moxifloxacin 
Column used in all 
instances 
Agilent Zorbax C18 150mm x 4.6mm x 3.5µ particle size 
Sample preparation See below* not required not required 
Column flow rate 
 
1.6 ml/min 0.75 ml/min 1 ml/min 
Column temperature 
 
45°C 40°C 40°C 
Injection volume 
 
60 µl 20 µl 20 µl 
UV detector setting 
 
340 nm - - 
Florescence detector: Ex - 284 nm 287 nm 
 
Em - 460 nm 463 nm 
Solvent A 50 mM KH2PO4 
Solvent B Acetonitrile : Isopropanol 4 : 1 v/v 
Gradient  solvent B 0 - 1 min 40% 0 - 1.0 min 35% 0 - 0.75 min 55% 
 
1 - 6 min linear to 60% 1.0 - 4.0 min linear to 65% 0.75 - 2.0 min linear to 70 % 
   
4.0 - 4.1 min return to 35% 2.0 - 2.1 min return to 55 % 
   
4.1 - 6 min 35% 2.1 - 6 min 55% 
Retention time 
 
2.08 min 
 
2.43 min 
 
1.62 min 
Run time 
 
6 min 
 
6 min 
 
6 min 
Equilibrium time 
 
3 min 
 
not required 
 
not required 
Table 3: HPLC detection of Isoniazid, Ofloxacin and Moxifloxacin 
 
 *Sample preparation of Isoniazid: For the detection of INH, 100μl of 10% TCA (trichloroacetic acid) and 100μl of INH-containing 
effluent sample were mixed and vortexed for 30 seconds. Hereafter, 40 μl of 1% metanolic cinnamaldehyde was added to the 200μl for 
derivatisation. 
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4.8 BACTEC 
All experiments with infectious material were carried out in a category-3 biosafety 
laboratory. 
4.8.1 Culturing of M. tuberculosis 
Clinical isolates of M. tuberculosis X51 XDR strain and M. tuberculosis H37Rv 
reference strain, banked in the Department of Medical Biochemistry, was cultured 
on L-J slant cultures and used for BACTEC analysis. 
 4.8.2 Solvents 
Depending on the biological activity of the compounds as well as the specific 
strain, concentration ranges were adjusted in relation to the minimum inhibitory 
concentration (MIC) of the compound (Table 4): 
 INH: H37Rv 
Reference Strain 
Oflox: X51 
XDR Strain 
Moxi: X51 
XDR Strain 
MIC 0.02 μg/ml 2 μg/ml 1 μg/ml 
Table 4: Minimum Inhibitory Concentrations of the relevant antimycobacterial 
drugs and their corresponding strains.  
All of the above antimycobacterial drugs were prepared in PBS (pH 7.4). 
Liposomal-drug preparations were made following the same procedure as 
previously described in Section 4.1. A dilution series was made of the respective 
drugs and their liposomal combinations to create a concentration range above and 
below the MIC.   
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4.8.3 Mycobacterial cultures and BACTEC determinations. 
Clinical and laboratory strains of M. tuberculosis were cultured in Middlebrook 
medium enriched with ADC enrichment medium. Continuous stirring was executed 
to ensure homogenous bacterial distribution and uniform aeration, allowing the 
cultures to grow reproducibly (< 1.0% difference). This procedure allows accurate 
assessment of manipulation of mycobacterial cultures with compounds. At a 
culture density of approximately A600 nm = 0.16 (1x McFarland), M. tuberculosis 
strain cultures was inoculated (0.1 ml) into 4 ml-BACTEC vials. Cultures in 
BACTEC were grown until a growth index (GI) of 500 - 700 was reached. This 
culture was used as the starter (primary) culture for BACTEC evaluation of 
antimycobacterial compounds in question on M. tuberculosis strains. Sterility of 
primary cultures was monitored by Z-N acid fast staining. The test was performed 
as follows: 0.1 ml of the primary culture was added to each of the fresh BACTEC 
vials along with 0.1 ml compound-containing-solution in their relevant 
concentrations according to their MICs. Controls were held at 1:100 dilution of the 
primary culture in the absence of the compound. The bacterial cultures were then 
incubated at 37ºC. The culture growth was monitored over a time period of 
approximately 14 days. When the control reached a maximum GI of 500, the 
experiment was completed, and the ΔGI values (the change in growth for every 24 
h doubling period) were determined for each concentration value to detect a 
positive (growth was witnessed) or negative (no growth witnessed) growth 
response. Control assays (with no drugs) were brought to the same solvent 
concentrations. 
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4.9 Entrapment efficiency 
An ÄKTA™ explorer FPLC (Amersham Pharmacia Biotech) system was used to 
remove free, untrapped drug from drug-loaded liposomes. An aliquot of the 
liposomal preparation was loaded onto a Superdex-75 column (Sigma), 16 x 53 
cm (bead diameter of 24 – 44 μm; fractionation range 300 – 70 000 MW). 
Detection of drugs was carried out at 273 nm for INH and 287 nm for the 
fluoroquinolones (λmax). Fractions containing drug-loaded liposomes were assayed 
using HPLC to determine the concentration (entrapment efficiency).  The column 
was eluted with 50 mM phosphate buffer containing 10 mM NaCl (pH 7.4) at a 
constant flow rate of 0.25 ml/min. 
 
4.10 Spectroscopic analyses 
The spectral properties of the Superdex-75 fractions were performed on a 
Beckman DU 640 spectrophotometric system. Fluorescence scans were 
conducted with a Perkin–Elmer LS50B luminescence spectrometer fitted with a 
well-plate reader. Excitation and emission wavelengths of Oflox and Moxi were 
287 nm and 474 nm respectively (excitation slit 2.5 nm; emission slit 5 nm; scan 
speed 500 nm/min) 
 
4.11 Surface tension determination 
Surface tension measurements of the drug/DPPC-liposomal preparations (All at 
same concentration values) were done using a DIGIDROP Contact Angle Meter 
by GBX. Hammilton syringes were used to calibrate the pixels by using a syringe 
needle of 0.73 mm. The syringe pump was set at rates varying between 0.005-
0.0075 ml/min depending on the droplet-formation speed of the sample. The 
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density of each sample was also recorded as to ensure accurate readings. The 
right and left contact angles were measured and averaged by the GBX software 
which automatically calculates the tangent to the droplet shape and the contact 
angle and 7 repeat tests were performed for each adhesive. This allowed 
calculations of the spreading rates by logarithmic fitting of the variations in angles 
and determination of the standard deviations.99  
 
 
Figure 8: A; Apparatus used for contact angle measurements (DIGIDROP, GBX, Bourg 
de Peage, France). 1: vertical syringe, for the formation of calibrated volume drops, 2: 
light source, 3: video camera, 4: adjustable platform, 5: needle tip, 6: drop as registered 
on screen, 7: substrate surface B; Open window of the DIGIDROP program used to 
measure Surface Tension.
99
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5. RESULTS 
The overall mean flux values of isoniazid (INH) across porcine bronchial tissue 
with and without DPPC/DPPC-liposomes are shown in Fig. 9. No statistically 
significant differences between the INH control (n = 4) and the INH with DPPC (n = 
4) could be demonstrated (p = 0.9345). On average, the mean steady state INH 
flux rates of the DPPC-liposomes (n = 4) decreased by 43.3% when compared to 
the INH control (p = 0.0173) and 44.2% when compared to the INH-DPPC 
combination (p = 0.0124), respectively. Steady state for INH, INH-DPPC and INH 
DPPC-liposomes were obtained after approximately at 8 to 10 hrs (p > 0.05). 
Figure 9: Overall mean flux values of isoniazid across porcine bronchial tissue with 
and without DPPC and DPPC-liposomes. 
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The overall mean steady-state flux values of Oflox across porcine bronchial tissue 
with and without DPPC/DPPC-liposomes are shown in Fig. 10. All three the 
preparations achieved steady state flux values within 2 hrs. On average, this is 4 – 
5 times shorter than the time taken for INH to reach these values. No statistically 
significant differences between the mean steady state flux values of OFLOX 
control (n = 5) and Oflox with DPPC-liposomes (n = 3) could be demonstrated (p = 
0.3122) with the latter having on average 16.4% lower flux values. Flux values for 
Oflox-DPPC (n = 6) were statistically significantly decreased by 35.1% when 
compared to the Oflox control (p = 0.0265) and non–significantly by 22.4% when 
compared to the Oflox DPPC-liposomes (p = 0.1724). Steady-state flux rates for 
Oflox and Oflox-DPPC were reached at approximately 8 hrs while Oflox DPPC-
liposomes demonstrated a steady-state within 4 – 6 hrs (p < 0.05).  
Figure 10: Overall mean flux values of ofloxacin across porcine bronchial tissue with 
and without DPPC and DPPC-liposomes. 
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The overall mean steady-state flux values of Moxi across porcine bronchial tissue 
with and without DPPC/DPPC-liposomes are shown in Fig. 11. As in the previous 
graph (Fig. 10), all three preparations achieved steady state flux rates within 2 hrs 
compared to the 8 – 10 hrs required for INH. No statistically significant differences 
between the Moxi control (n = 6) and the Moxi-DPPC (n = 6) mean steady-state 
flux values could be demonstrated (p = 0.1023) with the latter having on average 
24.6% lower flux values. Flux values for Moxi DPPC-liposomes (n = 4) were 
statistically significantly increased by 43.8% when compared to the MOXI control 
(p = 0.0065) and by 57.7% when compared to the Moxi-DPPC combination (p = 
0.0010). Steady state for Moxi and Moxi-DPPC were reached at approximately 4 
hrs while Moxi DPPC-liposomes demonstrated a steady state within 4 – 6 hrs (p > 
0.05).  
 
Figure 11: Overall mean flux values of moxifloxacin across porcine bronchial tissue 
with and without DPPC and DPPC-liposomes. 
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The overall growth index M. tuberculosis susceptibly testing of INH using the 
BACTEC 460™ system is shown in Fig. 12. The MIC of the H37Rv strain was 
confirmed at 0.02 μg/ml (See Table 5). 
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Figure 12: Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added. 
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The overall growth index M. tuberculosis susceptibly testing of INH-DPPC 
liposomes using the BACTEC 460™ system is shown in Fig. 13. The MIC of the 
H37Rv strain was confirmed at 0.02 μg/ml (See Table 6). 
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Figure 13: Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added. All drug concentrations displayed 
illustrate liposomal combinations. 
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In reference to Fig. 12 and Fig. 13, the overall susceptibly of the M. tuberculosis, 
H37Rv strain to various concentrations of isoniazid displayed in Table 5 and 
isoniazid, DPPC-liposomes is displayed in Table 6.  
Samples 
Isoniazid  
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 335 612.5 277.5 - - 
            
0.1 μg/ml 6.5 5.5 -1 100% s 
0.08 μg/ml 6 4.5 -1.5 101% s 
0.06 μg/ml 7.5 4 -3.5 101% s 
0.04 μg/ml 6.5 5 -1.5 101% s 
0.02 μg/ml 26.5 46.5 20 93% s 
0.01 μg/ml 279 386 107 61% r 
0.005 μg/ml 310 424.5 114.5 59% r 
Table 5: Susceptibility of M. tuberculosis, H37Rv strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of INH without DPPC-
liposomes. GI.1: Growth index day 1, GI.2: Growth index day 2, ΔGI: change in growth, R/S: 
resistant/susceptible.  
Samples 
Isoniazid DPPC-liposomes 
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 277.5 500.5 223 - - 
DPPC 241.5 457 215.5 3% r 
0.1 μg/ml 5.5 2 -3.5 102% s 
 0.08 μg/ml 4 4.5 0.5 100% s 
0.06 μg/ml 3 3.5 0.5 100% s 
0.04 μg/ml 3.5 3 -0.5 100% s 
 0.02 μg/ml 5 5.5 0.5 100% s 
0.01 μg/ml 45 84 39 83% s 
 0.005 μg/ml 272.5 486.5 214 4% r 
Table 6: Susceptibility of M. tuberculosis, H37Rv strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of INH with DPPC-
liposomes. GI.1: Growth index day 1, GI.2: Growth index day 2, ΔGI: change in growth, R/S: 
resistant/susceptible. 
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The overall growth index M. tuberculosis susceptibly testing of ofloxacin using the 
BACTEC 460™ system is shown in Fig. 14. The MIC for the X51 XDR strain was 
confirmed to be at 0.2 μg/ml (See Table 7).  
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Figure 14: Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added.  
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The overall growth index M. tuberculosis susceptibly testing of ofloxacin DPPC-
liposomes using the BACTEC 460™ system are shown in Fig. 15. The MIC for the 
X51 XDR strain was confirmed to be at 0.2 μg/ml (See Table 8). 
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Figure 15: Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added. All drug concentrations displayed 
illustrate liposomal combinations. 
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In reference to Fig. 14 and Fig. 15, the overall susceptibly of the M. tuberculosis, 
X51 XDR strain to various concentrations of ofloxacin is displayed in Table 7 and 
ofloxacin with DPPC-liposomes is displayed in Table 8. 
Table 7: Susceptibility of M. tuberculosis, X51 XDR strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of ofloxacin. GI.1: Growth 
index day 1, GI.2: Growth index day 2, ΔGI: change in growth, R/S: resistant/susceptible. 
Samples 
Ofloxacin DPPC-liposomes 
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 191 508.5 317.5 - - 
DPPC 161 415 254 20% r 
8 μg/ml 1 0 -1 100% s 
6 μg/ml 3 5 2 99% s 
4 μg/ml 27.5 1 -26.5 108% s 
2 μg/ml 13.5 2 -11.5 104% s 
1 μg/ml 22 39.5 17.5 94% s 
0.5 μg/ml 115 234.5 119.5 62% r 
0.25 μg/ml 177 440 263 17% r 
Table 8: Susceptibility of M. tuberculosis, X51 XDR strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of ofloxacin with DPPC-
liposomes. GI.1: Growth index day 1, GI.2: Growth index day 2, ΔGI: change in growth, R/S: 
resistant/susceptible. 
Samples 
Ofloxacin  
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 191 508.5 317.5 - - 
            
8 μg/ml 0 0 0 100% s 
6 μg/ml 0 0.5 0.5 100% s 
4 μg/ml 2.5 1.5 -1 100% s 
2 μg/ml 13.5 22.5 9 97% s 
1 μg/ml 80.5 180 99.5 69% r 
0.5 μg/ml 151.5 344.5 193 39% r 
0.25 μg/ml 143 265.5 122.5 61% r 
Stellenbosch University http://scholar.sun.ac.za
 44 
 
The overall growth index M. tuberculosis susceptibly testing of moxifloxacin using 
the BACTEC 460™ system is shown in Fig. 16. The MIC for the X51 XDR strain 
was confirmed to be at 0.1 μg/ml (See Table 9) 
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Figure 16: Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added 
  
Stellenbosch University http://scholar.sun.ac.za
 45 
 
The overall growth index M. tuberculosis susceptibly testing of moxifloxacin 
DPPC-liposomes using the BACTEC 460™ system are shown in Fig. 17. The MIC 
for the X51 XDR strain was confirmed to be at 0.1 μg/ml (See Table 10) 
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Figure 17. Extracellular drug testing at 1 x 107 M. tuberculosis per BACTEC 460™ vial 
containing 4 ml Middlebrook 7H12 medium. For control, M. tuberculosis was inoculated into 
BACTEC 460™ vials with no inhibitor or drug added. All drug concentrations displayed 
illustrate liposomal combinations. 
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In reference to Fig. 16 and Fig. 17, the overall susceptibly of the M. tuberculosis, 
X51 XDR strain to various concentrations of ofloxacin is displayed in Table 9 and 
ofloxacin DPPC-liposomes is displayed in Table 10. 
Samples 
Moxifloxacin  
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 191 508.5 317.5 - - 
            
 4 μg/ml 0 1 1 100% s 
3 μg/ml 0.5 0.5 0 100% s 
2 μg/ml 0.5 0 -0.5 100% s 
1 μg/ml 6.5 9 2.5 99% s 
0.5 μg/ml 23.5 49.5 26 92% r 
0.25 μg/ml 79.5 176.5 97 69% r 
0.125 μg/ml 118 280.5 162.5 49% r 
Table 9: Susceptibility of M. tuberculosis, X51 XDR strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of moxifloxacin without 
DPPC liposomes. GI.1: Growth index day 1, GI.2: Growth index day 2, ΔGI: change in 
growth, R/S: resistant/susceptible. 
Samples 
Moxifloxacin DPPC-liposomes 
GI.1 GI.2 ΔGI % of Inhibition R/S 
Control 191 508 317 - - 
DPPC 161 415 254 20% r 
 4 μg/ml 0.5 0.5 0 100% s 
3 μg/ml 0.5 1.5 1 100% s 
2 μg/ml 0.5 1 0.5 100% s 
1 μg/ml 3 5 2 99% s 
0.5 μg/ml 17.5 29 11.5 96% s 
0.25 μg/ml 86.5 202 115.5 64% r 
0.125 μg/ml 144 347 203 36% r 
Table 10: Susceptibility of M. tuberculosis, X51 XDR strain, isolates as determined by the 
BACTEC 460™ system when exposed to various concentrations of moxifloxacin DPPC-
liposomes. GI.1: Growth index day 1, GI.2: Growth index day 2, ΔGI: change in growth, R/S: 
resistant/susceptible. 
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Entrapment efficiency of drug–liposomal preparations were determined on eluted 
fractions after chromatography on Superdex–75 as shown in Fig. 18. Analyses, 
using HPLC, of eluted INH fractions showed entrapment efficiency for INH to be 
53%. For Oflox and Moxi, entrapment efficiency was calculated to be 46.6% and 
43.3% respectively.  Moxifloxacin, Ofloxacin and INH Liposomes Superdex 75
Chromatography
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Figure 18: Gel-filtration chromatography of drug combined DPPC liposomal preparations on 
a 16 x 53 cm Superdex–75 column equilibrated with 50 mM phosphate buffer containing 100 
mM NaCl. 
Ultraviolet spectrophotometry of INH and INH–DPPC entrapped liposomes after 
gel filtration is shown in Fig. 19. Spectrum (b) showed the characteristic UV 
absorbance maximum of INH at 273 nm as depicted in (a).  
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Figure 19(a): Absorption spectra of INH. (b): Absorption spectra of INH Liposomes (273 nm 
λmax) after gel filtration on a Superdex-75 column.  
To verify the presence of liposomes in the fractions collected after gel filtration, 
microscopy was done. Fig. 20 clearly depicts liposomes and the sizes ranging 
from 4.5 μm in diameter to smaller ones of approximately 780 nm in diameter. 
Liposomal clusters were also seen in the image.  
 
 Figure 20: DPPC liposomes visualised by optical microscopy. 
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Ultraviolet spectrophotometry and fluorescence spectrometry of eluted fraction 
after Superdex chromatography verified Oflox and Moxi entrapped liposomes (Fig. 
21 – 24).  
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Figure 21: The absorption spectra of Oflox, Oflox liposomes before and a representative 
fraction of Oflox–liposomes after fractionation on a Superdex–75 column.  
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Figure 22: The fluorescence spectra of Oflox, Oflox liposomes before and a representative 
fraction of Oflox–liposomes (excitation at 287 λmax) after fractionation on a Superdex–75 
column.  
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Moxifloxacin UV Spectra
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Figure 23: The absorption spectra of Moxi, Moxi liposomes before and the representation 
fraction of Moxi–liposomes after fractionation on a Superdex–75 column. 
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Figure 24: The fluorescence spectra of Moxi, Moxi liposomes before and the representation 
fraction of Moxi–liposomes (excitation at 287 λmax) after fractionation on a Superdex–75 
column. 
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Figure 25 displays the surface tension of INH, Oflox and Moxi within their DPPC-
liposomal combinations compared to that of DPPC-liposomes only, DPPC and 
PBS. The increases of surface tension seen for the drug-liposomal combinations 
compared to that of the DPPC-liposomes were found to be statistically significant. 
However, when taking into account the surface tension values of PBS and water 
(±72 mN/m), the increases were not found to be significant.  
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Figure 25: The surface tension values of the different drug-DPPC liposome combinations in 
reference to PBS and DPPC. INH: Isoniazid entrapped DPPC-liposomes, Oflox: Ofloxacin 
entrapped DPPC-liposomes, Moxi: Moxifloxacin entrapped DPPC-liposomes. 
  
Bar = SEM 
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Fig. 26 & 27 displays images of drug-liposomal preparations, before and after 
extrusion. Multi–lamellar vesicles (MLV) are seen in high magnification before 
extrusion through a 100 nm pore size polycarbonate filter. In Fig. 27, the sample is 
more homogenous after extrusion and the liposomes are smaller in diameter and 
single–lamellar vesicles (SLV) are noted. 
 
Figure 26: Un-extruded drug containing liposomes under high magnification illustrating 
MLV.  
 
Figure 27: Extruded drug containing SLV.  
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6. DISCUSSION 
 
The future of pharmacotherapy for many disorders may lie in drug delivery routes 
other than oral administration. In particular, growing interest has been given to the 
lung as well as other absorptive mucosae as non-invasive administration routes for 
systemic delivery for therapeutic agents. Which is more, further interest has been 
shown in targeted drug delivery. Site specific drug delivery pursues to concentrate 
medication in the tissues of interest while reducing the relative concentration of the 
medication in the remaining tissues, improving the efficacy of the drug, minimizing 
systemic exposure and therefore circumventing adverse effects.100 The possibility 
of inhalable formulations through the pulmonary route allows for faster onset and 
the drug is delivered directly to the target organ. There has been an increasing 
amount of interest in the transmembrane diffusion kinetics of a variety of chemical 
compounds across different tissues. This can be credited to a better 
understanding of factors that influence or govern transmembrane diffusion 
processes of chemical compounds in the context of: rates of transmembrane 
absorption, permeability enhancer characteristics and actions as well as 
therapeutic-agent delivery formulations. We decided to study the in vitro diffusion 
kinetics of antitubercular drugs across bronchial tissue as there is only a limited 
amount of information available on this subject. Since pulmonary tuberculosis (TB) 
continues to be a major infectious burden worldwide, the relevance of this study 
holds great value when looking at the possibility of pulmonary administration of 
drug loaded surfactant.  
The ability of substances to diffuse through epithelial barriers depends not only on 
the properties of the barriers involved, but also on the chemical nature, size and 
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conformation, lipid/water partition coefficient, and degree of ionisation of the 
permeant molecules tested.94,101,102 One of the major difficulties limiting the 
effectiveness of absorptive mucosa is the cellular membrane. It acts as a barrier to 
macromolecules and to most polar molecules, but it is relatively permeable to 
water and small lipophilic molecules. Rojanasakul et al. compared the permeability 
of the membrane barrier and charge selectivity in various rabbit epithelia and they 
concluded that pulmonary epithelium is one of the most effective mucosal surfaces 
for drug delivery purposes.103 This is probably due to its high membrane 
permeability and large absorptive surface area.  
The molecular diffusion of drugs across bronchial tissue can be viewed as 
consisting of a continuous epithelium, collagen fibre network and interstitium. 
Depending on the physiochemical properties of a permeant, the diffusional 
resistance offered by the individual layers can vary greatly. The main barrier 
offering high resistance to the diffusion of hydrophilic and charged molecules is the 
lipoidal nature of bronchial epithelium which consists of pseudostratisfied, ciliated 
columnar epithelium.88,89,104  
The primary drug used in the current chemotherapy of TB is INH, the hydrazide of 
isonicotinic acid. It is a small molecule (Mw = 137) and it highly water soluble. The 
two second line drugs, Oflox (Mw = 361) and Moxi (Mw = 401) are included in the 
treatment regimen when patients are diagnosed with MDR-TB. Both of these 
drugs are large molecules from the fluoroquinolone antimicrobial class that are 
amphoteric/amphiphillic in nature. The main difficulties associated with treatment 
include dose related adverse effects due to toxicity, prolonged treatment duration 
and the fact that drugs may not reach atelectatic areas of the lung. Thus, the 
administration of INH, Oflox, and Moxi via the respiratory route is an exciting 
Stellenbosch University http://scholar.sun.ac.za
 55 
 
possibility. Recently, the idea of incorporating the spreading properties of DPPC 
as a drug delivery agent of INH was studied by Chimote and Banerjee.62,74,105 This 
approach can serve the dual purpose of alveolar stabilisation by surfactant action 
and drug targeting. For this reason, we decided to investigate the permeation and 
enhancement of the three antimycobacterial drugs used in the current TB regimen 
with DPPC/DPPC liposomes through porcine bronchial tissue.  
The flux values of INH and INH-DPPC display no significant differences in 
permeability through bronchial tissue (Fig. 9). Due to the hydrophilic characteristic 
of INH, it will most probably take the intracellular route of diffusion but when in 
combination with DPPC, the disruption of intercellular lipids could possibly reduce 
restriction to molecular movement allowing for intercellular movement instead. 
However, when DPPC is present alone at physiological temperatures, it adsorbs 
slowly to the pulmonary air-liquid interface to form a surfactant monolayer that 
might explain the significant decrease of INH flux value of 43.3% with the 
liposomal combination to that of INH, in our studies. This is indicative of the 
possible interference of diffusion processes by the formulation nature of DPPC 
with drug. Due to the hydrophilic nature of INH along with the slow adsorption of 
DPPC in ripple phase (at 36.5 °C), it will reside within the hydrophilic nucleus of 
the liposome offering the explanation of the retarded diffusion.106 
Considering the importance of fluoroquinolone drug delivery and localisation in 
bronchial tissue during infection; the diffusion kinetics of Oflox and Moxi were 
studied. Both drugs, and their relative DPPC preparations, achieved steady state 
flux values within 2 hrs compared to that of INH (Fig.10 and 11). A possible 
explanation for this difference may be that the permeation of these drugs through 
the epithelium could be ascribed to transcellular diffusion compared to the 
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paracellular route followed by INH. Also, less drug was able to diffuse compared to 
that of INH through the bronchial tissue. As the magnitude of the flux rates of the 
various permeants across bronchial tissue are related to molecular size, with the 
larger compounds having lower flux rates. These results are in agreement with 
previous permeability studies reported for human vaginal, small intestinal and 
colonic mucosa.107  
When Oflox and Moxi were in combination with DPPC, the retardation found could 
be due to the fact that the DPPC may have aided solubilisation of the lipophilic 
fluoroquinolones, thereby negatively affecting their partitioning from solution into 
the tissue. Moreover, DPPC may merely have increased competition with Oflox 
and Moxi for the transmembrane permeation routes. Another explanation for the 
retardation of Oflox across porcine bronchial tissue in combination with DPPC and 
DPPC-liposomes could also be that Oflox flux rates were already at a maximum.  
The liposomal preparation of Moxi significantly enhanced the flux values by 43.6%. 
This is contrary to in the DPPC-drug combination where retardation in flux was 
found. A study done by Neves et al. investigated moxifloxacin in liposomes of 
dimyristoyl-L-α-phosphatidylcholine or dimyristoyl-L-α-Phosphatidylglycerol.108 
They observed that the partition coefficient of moxifloxacin is larger than those 
reported for most of the other fluoroquinolones This could be a consequence of 
the structural changes observed in the molecule itself, which in turn changes its 
acid/base properties. The authors further stated that the molecule must be located 
near the phospholipid headgroups, similar to other fluoroquinolones, but they 
suspect contributions from a hydrophobic component as well. Furthermore, at 
physiological pH, Moxi exists 93% in the zwitterionic and 7% in the cationic form 
whereas Oflox exist 90% in the zwitterionic and 10% in the anionic form. These 
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small differences have important consequences when considering their partition 
coefficient within liposomal suspension. The different flux values observed for Moxi 
within the liposomal form to that of Oflox liposomes can also be explained by the 
associated presence of the substituent groups in their structures (Fig. 6). These 
groups change the pKa values of these drugs, meaning that at physiological pH 
the drugs exist not only in a zwitterionic form but also in a cationic form that 
interacts much more strongly with the negatively charged lipid heads. On the other 
hand, the presence of these substituent groups may require that these drugs insert 
themselves into the bilayers in a different way, thus enhancing electrostatic 
interactions. In such a situation, hydrophobic and electrostatic interactions may 
reinforce each other. 108  
The liposomal formulations containing the antimycobacterial drugs were tested 
against MTB strains for the accurate determination of susceptibly. Unlike the 
traditional methods of observing visible mycobacterial growth in culture media, this 
technique monitors mycobacterial growth by measuring 14CO2 produced by the 
culture medium due to mycobacterial growth (14C labelled palmitic acid present in 
the growth medium). The standard H37Rv strain was used for the susceptibility 
testing of MTB to INH (as it is a first-line drug) and the XDR strain X51 was used 
for the susceptibility testing of MTB to Oflox and Moxi due to their position as 
second line drugs in the treatment of MDR-TB. Furthermore, all three drugs 
displayed increased antimycobacterial activity to their relevant strains when in 
combination with DPPC-liposomes that was as effective as their unformulated 
counterparts in terms of their in vitro efficacy. INH, having a MIC of 0.02 µg/ml, 
displayed a 22% increase in bacterial susceptibility when in combination with the 
DPPC-liposomes at 0.01 µg/ml (half of MIC). The same increased bacterial 
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susceptibility was found for the fluoroquinolones. Oflox–DPPC liposomes 
displayed a 25% increase in susceptibility at 1 µg/ml (half of MIC) and, although 
the population was still seen to be resistant, 0.5 µg/ml (quarter of MIC) displayed 
an increased susceptibility of 23%. Moxi–DPPC liposomes, with increased 
susceptibility of 4%, did not alter the MIC to such an extent as Oflox and INH. 
However, one interesting factor to take into consideration is the bactericidal activity 
of DPPC alone. Un-loaded DPPC liposomes displayed a 3% decrease in 
mycobacterium growth for the H37Rv strain and a 20% decrease in growth for the 
XDR strain X51.  
There are many possible suggestions for the increased susceptibility of MTB to 
drug-loaded DPPC liposomes. One explanation is presented by a study done by 
Stoops et al where the authors stated that “surfactants are proficient in removing 
MTB's shield (TDM coat) and, because they are well known as cell permeabilising 
agents, they may also enhance the effectiveness of antibiotics”.72 This view refers 
to the increased concentration/permeability of drug into the intracellular space of 
the bacteria rather than the increase in its activity. A supporting explanation is 
brought to the table by Neves et al.108 With all the considerations to take into 
account for the permeability of these drugs through bronchial tissue (i.e. partition 
coefficient), these susceptibility results suggest that the enhanced activity of the 
antimycobacterial drugs may be related to a more facilitated entrance into the 
bacterial cell. Perhaps by including a mediator step involving electrostatic 
interaction with a hydrophobic component (DPPC liposome); this step then 
controls the extent or orientation of insertion and improves the electrostatic 
interaction.108,109 
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Entrapment efficiency depends on the interaction of the drug molecules and their 
partition coefficient. Hydrophillic drugs like INH are readily entrapped within the 
aqueous core of the liposomal vesicle, whereas hydrophobic/amphoteric 
molecules like Oflox and Moxi are localised within the bilayers of the vesicles. The 
higher entrapment of INH (53%) to that of the fluoroquinolones (46,6% for Oflox 
and 43,3% for Moxi, respectively) could be attributed to the entrapment of INH in 
the multi-lamellar compartments of MLVs.62 Even with these relatively low 
entrapment percentages, drug susceptibility testing of MTB was not hindered. 
Even more so, the liposomal preparations increased MTB sensitivity to the relative 
drugs at concentrations below their respective MICs.  
Different temperatures can alter the thermotropic behavioural nature of DPPC in 
the presence of a foreign molecule in the biomembrane of the vesicle as a function 
of its own physicochemical properties. Under physiological pH, ofloxacin is in its 
higher hydrophobic form and hence, able to permeate bilayers, slightly perturbing 
the hydrophobic zone of the membrane.110 Furthermore, DPPC in the presence of 
higher temperatures (±45°C) offers a drug-rich domain between the transition of 
the ripple and liquid crystal phase. The ofloxacin carboxyl group can be twisted 
(might be applicable for Moxi as well) out of plane as in the zwitterionic form due to 
orientation and change in pKa within the liposomal membrane. The situation can 
possibly be exacerbated further due to the heterocyclic ring strain and its 
orientation when a biological target is nearby such as living bacteria (MTB) that 
maintain a proton driving force across the cytoplasmic membrane. For these 
reasons, Fresta et al stated that in the case of amphoteric fluoroquinolones, an 
improved activity as a function of the charged/un-charged species of drugs on the 
cytoplasmic drug accumulation and on antimycobacterial efficacy is more likely the 
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effect rather than the accumulation of uncharged forms.110 This allows for the 
understanding of the connection to the supporting explanation by Neves et al.105 
Conversely, this is in difference to Stoops et al.72 However, all three authors do 
agree that the efficacy and permeation are influenced by the physicochemical 
properties of the drugs as well as the membrane properties of MTB. DPPC thus 
alters the membrane to become more fluid enabling increased permeation.  
By itself, DPPC exhibits slow and poor interfacial adsorption at temperatures 
below its gel to liquid transition temperature (41 °C). DPPC adsorption yielded a 
surface tension value of 44.7 ± 0.6 mN/m. The surface tensions attained by the 
drug-loaded DPPC liposomes are as follows: INH–DPPC (1:1 ratio by weight) ± 46 
mN/m, Oflox–DPPC (1:1 ratio by weight) ± 45 mN/m and Moxi–DPPC (1:1 ratio by 
weight) ± 43 mN/m. Thus, a statistically significant increase (p < 0.05) in the DPPC 
adsorption was observed on addition of antitubercular drugs to unloaded DPPC 
liposomes (± 35 mN/m). The isoniazid molecules could probably interact with the 
positively charged polar head groups of the DPPC molecules. Since very little 
amount of INH is adsorbed at the interface its interaction with the hydrophobic tails 
of the DPPC molecules seems less of a possibility. At physiological pH, INH is 
neutral and hence does not cause a direct difference in the ionised status of the 
DPPC molecule. Furthermore, the presence of the large fluoroquinolone 
molecules can possibly decrease the proximity between the DPPC molecules 
deterring their reorientation and packing of the hydrocarbon tails.105 When taking 
into account the surface tension of water ±72mN/m, these minimal increases in 
surface tension do not alter the integrity of DPPC to a large extent that its ability to 
reopen atelectatic areas within the lung will be compromised.  
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In conclusion, the possibility of pulmonary delivery of INH, Oflox and Moxi along 
with an exogenous surfactant as a drug carrier was the primary theme of this 
study. Site-specific drug administration to improve the reach of antimycobacterials 
allows for lower dosages and can prevent undesired adverse-effects due to 
systemic toxicity. The drug loaded DPPC liposomes indicated a wide variation in 
their permeability characteristics compared to their counterparts through porcine 
bronchial tissue. This is indicative that there are definitive interactions between the 
drug and DPPC liposomes, drug and tissue, as well as DPPC liposomes and 
tissue. This study thus demonstrated the usefulness of the in vitro flow-through 
perfusion model to study the absorption characteristics of bronchial tissue in this 
area of research.  
 
Furthermore, the drug loaded liposomes retained antimycobacterial activity in the 
BACTEC system thus proving that drug loaded DPPC liposomes exhibited a 
potential of being effective in vivo as surfactant-based drug delivery system. This 
study has been one of the first steps towards developing surfactant based drug 
delivery systems for pulmonary TB.  
  
Stellenbosch University http://scholar.sun.ac.za
 62 
 
7. REFERENCES 
 
1. Pettit DK, Gombotz WR. The development of site-specific drug delivery systems 
for protein and peptide biopharmaceuticals. TIBTECH. 1998; 16: 343-349. 
 
2. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: Recent 
developments and prospects. Crit Rev Ther Drug Carrier Syst. 2002; 19: 425-
498. 
 
3. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci. 2000; 89: 940-945. 
 
4. Hussain A, Arnold JJ, Khan MA, Ahsan F. Absorption enhancers in pulmonary 
protein delivery. J Control release. 2004; 94: 15-24. 
 
5. Kharasch VS, Sweeny TD, Fredberg J, Lehr J, Damokosh AI, Avery ME, Brain 
JD. Pulmonary surfactant as a vehicle for intratracheal delivery for technetium 
sulphur colloid and pentamidine in hamster lungs. Am Rev Respir Dis. 1991; 144: 
909-913. 
 
6. Lachman B, Gommers D. Is it rational to treat pneumonia with exogenous 
surfactant? Eur Respir J. 1993; 6: 1437-1438. 
 
7. Van’t Veen A, Gommers D, Mouton JW, Kluytmans JA, Krijt EJ, Lachmann B. 
Exogenous pulmonary surfactant as a drug delivering agent: Influence of 
antibiotics on surfactant activity. Br J Pharmacol. 1996; 118: 593–598. 
Stellenbosch University http://scholar.sun.ac.za
 63 
 
 
8. Larsson M. A surface phase Model of the Alveolar lining: Ultra-structural Analysis 
and in vivo Applications. Thesis, Lund University, Malmö, 2002. 
 
9. Smola M, Vandamme T, Sokolowski A. Nanocarriers as pulmonary drug delivery 
systems to treat and to diagnose respiratory and non-respiratory diseases. Int J 
Nanomedicine. 2008; 3: 1-19. 
 
10. Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lung. Adv Drug 
Del Rev. 1990; 5: 149-161. 
 
11. WHO, Global tuberculosis control: Epidemiology, strategy, financing: WHO report 
WHO/HTM/TB/2011.16 2011. 
 
12. Nerlich AG, Haas CJ, Zink A, Szeimies U, Hagedorn HG. Molecular evidence for 
tuberculosis in an ancient Egyptian mummy. Lancet. 1997; 350:1404.  
 
13. Salo WL, Aufderheide AC, Buikstra J, Holcomb TA. Identification of 
Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc 
Natl Acad Sci USA 1994; 91: 1091-1094. 
 
14. Koch R, Die Atiologie van der Tuberkulose. Berliner Kliniscben Wocbenshift. 
1882; 15: 221-230. 
 
15. McCarthy OR, The key to the sanatoria. J R Soc Med. 2001; 94: 413-417. 
Stellenbosch University http://scholar.sun.ac.za
 64 
 
 
16. WHO, Global tuberculosis control: Epidemiology, strategy, financing : WHO 
report. WHO/HTM/TB/2009.411, 2009.  
 
17. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G. Multidrug-resistant and 
extensively drug-resistant tuberculosis: Implications for the HIV epidemic and 
antiretroviral therapy rollout in South Africa. J Infect Dis. 2007; 196: 482–490.  
 
18. Andrews J, Basu S, Scales D, Smith-Rohrberg Maru D. XDR-TB in South Africa. 
PLOS Medicine. 2007; 4: 770-771. 
 
19. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, 
Liversage T, Masibi M, van Helden PD, Warren RM, Victor TC. Emergence of 
increased resistance and extensively drug-resistant tuberculosis despite 
treatment adherence. South Africa. Emerg Infect Dis. 2010; 16: 264-271. 
 
20. Wise J, Southern Africa is moving swiftly to combat the threat of XDR-TB. Bull 
World Health Organ. 2006; 84: 924-925. 
 
21. Nuermberger EL, Spigelman MK, Yew WW. Current development and future 
prospects in chemotherapy of tuberculosis. Respirology. 2010; 15: 764–778. 
 
22. Standard Treatment Guidelines and essential Medicine list for South Africa 2012 
Edition. 
 
Stellenbosch University http://scholar.sun.ac.za
 65 
 
23. Department of Health. The South African national tuberculosis control 
programme practical guidelines, 2004.  
 
24. World Health Organization. Global Tuberculosis Control: Epidemiology, Planning, 
Financing: WHO Report 2009. WHO/HTM/TB/2009.411. World Health 
Organization, Geneva, 2009. 
 
25. Zignol M, Hosseini MS, Wright A, Lambregts-van Weezanbreek C, Nunn P, Watt 
CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. J 
Infect Dis. 2006; 194: 479-485. 
 
26. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. 
N Engl J Med. 2007; 356: 656–659. 
 
27. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis (Review). 
Cochrane Database Syst Rev. 2008; 1: CD004795. 
 
28. Sosnik A, Carcabosa AM, Glisoni RJ, Moretton MA, Chiapetta DA. New old 
challenges in tuberculosis: Potentially effective nanotechnologies in drug delvery. 
Adv Drug Deliv Rev. 2009; 62: 547-559. 
 
29. Dye C. Global epidemiology of tuberculosis. Lancet. 2006; 367: 938-940. 
 
Stellenbosch University http://scholar.sun.ac.za
 66 
 
30. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral 
therapy in patients with tuberculosis: Drug interactions, toxicity, and immune 
reconstitution inflammatory syndrome. J Infect Dis. 2007; 196: S63-75.  
 
31. Parrish NM, Dick JD, Bishai WR. Mechanism of latency in Mycobacterium 
tuberculosis. Trends Microbiol. 1998; 6: 107-112. 
 
32.  Wayne LG, Hayes LG. An in vitro model for sequential study of down shift of 
Mycobacterium tuberculosis through two stages of non-replicating persistence. 
Infect Immun. 1996; 64: 2062-2069. 
 
33. Barry 3rd CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger, D, 
Wilkinson, RJ, Young D. The spectrum of latent tuberculosis: Rethinking the 
biology and intervention strategies. Nature Rev. 2009; 7:  845-855. 
 
34. Dick T, Dormant tubercle bacilli: The key to more effective TB chemotherapy? J 
Antimicrob Chemother. 2001; 47: 117-118. 
 
35. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of 
serious side effects from first-line antituberculosis drugs among patients treated 
for active tuberculosis. Am J Respir Crit Care Med. 2003; 167: 1472-1477. 
 
36.  Maartens G, Wilkinson RJ. Tuberculosis. Lancet. 2010; 370: 2030-2043. 
 
Stellenbosch University http://scholar.sun.ac.za
 67 
 
37. Barry 3rd CE. New horizons in the treatment of tuberculosis. Biochem Pharmacol. 
1997; 54: 1165-1172.  
 
38. Haagsma AC, Podasca I, Koul A, Andries K, Guillemont J, Lill H, Bald D. Probing 
the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP 
synthase. PLoS ONE. 2011; 6: e23575. doi:10.1371/journal.pone.0023575. 
 
39. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, 
Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino 
JC, De Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys 
W, de Beule K, Andries K, Mc Neely DF. The diarylquinoline TMC207 for 
multidrug-resistant tuberculosis. N Engl J Med. 2009; 360: 2397-2405. 
 
40. Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M, Grange 
JM, Treatment of tuberculosis: Present status and future prospects. Bull World 
Health Organ. 2005; 83: 857-865. 
 
41. Casenghi M, Cole ST, Nathan CF. New Approaches to Filling the Gap in 
Tuberculosis Drug Discovery. PLoS Med. 2007; 4: 1722-1725. 
 
42. Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New 
drugs against tuberculosis: problems, progress, and evaluation of agents in 
clinical development. Antimicrob Agents Chemother. 2009; 53: 849-862. 
 
Stellenbosch University http://scholar.sun.ac.za
 68 
 
43. McKinney JD. In vivo veritas: The search for TB drug targets goes live. Nat Med. 
2000; 6: 1330-1333. 
 
44. Casenghi M, Schoen-Angerer T. Development of new drugs for TB 
chemotherapy: Analysis of the current drug pipeline. MSF, 2006: 1-48. 
 
45. Dover LG, Coxon GD. Current status and Research strategies in Tuberculosis 
Drug Development. J Med Chem. 2011; 54: 6157-6165. 
 
46. Health Systems Trust, Hopeful results from study of new TB drug cocktails. 24 
July 2012. 
 
47. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald 
PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and 
moxifloxacin combinations: A randomised trial. Lancet. Early Online Publication, 
2012. doi:10.1016/S0140-6736(12)61080-0. 
 
48. Cox H, Ford N. Linezolid for the treatment of complicated drug resistant 
tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 
2012; 16: 447-454. 
 
49. Gregoriadis G, Wills EG, Swain CP, Tavill AS. Drug carrier potential of liposomes 
in cancer chemotherapy, Lancet. 1974; 1: 1313–1316. 
 
Stellenbosch University http://scholar.sun.ac.za
 69 
 
50. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid 
Interface Sci. 2001; 6: 66-77. 
 
51. Sato T, Sunamoto J. Recent aspects in the use of liposomes in biotechnology 
and medicine. Prog Lipid Res. 1992; 31: 345–372. 
 
52. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int 
J Pharm. 1997; 154: 123-140. 
 
53. Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposome 
encapsulated antibiotics for therapy of intracellular Mycobacterium avium 
infection. Antimicrob. Agents Chemother. 1995; 39: 2104–2111. 
 
54.  Duzgunes N, Flasher D, Reddy MV, Luna-Herrera J, Gangadharam PR. 
Treatment of intracellular Mycobacterium avium complex infection by free and 
liposome encapsulated sparfloxacin. Antimicrob Agents Chemother. 1996; 40: 
2618–2621. 
 
55. Deol P, Khuller GK. Lung specific stealth liposomes: Stability, biodistribution and 
toxicity of liposomal antitubercular drugs in mice. Biochem Biophys Acta. 1997; 
1334: 161–172. 
 
56. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress 
and challenges. J Antimicrob Chemother. 2005; 55: 430–435. 
 
Stellenbosch University http://scholar.sun.ac.za
 70 
 
57. Gill S, Löbenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. Nanoparticles: 
Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - A 
review. J Biomed Nanotechnol. 2007; 3: 107–119. 
 
58. Azarmi S, Roa WH, Löbenberg R. Targeted delivery of nanoparticles for the 
treatment of lung diseases. Adv Drug Deliv Rev. 2008; 60: 863–875. 
 
59. Ohashi K, Kabasawa T, Ozeki T, Okada H. One-step preparation of 
rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol 
microspheres using a four-fluid nozzle spray drier for inhalation therapy of 
tuberculosis. J Control Release. 2009; 134: 19–24. 
 
60. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery 
agent. Adv Drug Deliv Rev. 2001; 47:197–207. 
 
61. Chimote G, Banerjee R. Lung surfactant dysfunction in tuberculosis: Effect of 
mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity. 
Colloids Surf B: Biointerfaces. 2005; 45: 215–223. 
 
62. Chimote G, Banerjee R. In Vitro Evaluation of inhalable isoniazid-loaded 
surfactant lipsomes as an adjunct therapy in pulmonary tuberculosis. J Biomed 
Mater Res B Appl Biomater. 2010; 94: 1–10. 
 
Stellenbosch University http://scholar.sun.ac.za
 71 
 
63. Wang Z, Schwab U, Rhoades E, Chess PR, Russell DG, Notter RH. Peripheral 
cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function 
Tuberculosis (Edinb). 2008; 88: 178–186. 
 
64. Kulik NM. Inhalation of cycloserine in the complex therapy of patients with 
pulmonary tuberculosis. Probl Tuberk. 1967; 45:38-40. 
 
65. Kulik NM. Inhalation therapy of tuberculosis patients with antitubercular agents of 
the first and second line. Probl Tuberk. 1974: 34-37. 
 
66. Kulik NM. Treatment of pulmonary tuberculosis by the inhalation of aerosols of 
antibacterial preparations and pathogenetic agents. Probl Tuberk. 1980:40-42. 
 
67. Pilipchuk NS, Protsiuk RG. Effect of inhalation of aerosols of antitubercular 
preparations on pulmonary surfactant. Vrach Delo. 1986: 21-5. 
 
68. Protsiuk RG. Effect of the inhalation of tuberculostatic aerosols on the dynamics 
of bacterial excretion in pulmonary tuberculosis patients. Probl Tuberk. 1983: 38-
42. 
 
69. Protsiuk RG. Effect of the inhalation of drug aerosols on external respiration in 
pulmonary tuberculosis patients. Klin Med (Mosk). 1985; 63: 50-55. 
 
 72 
 
70. Semenova EV. Basis for the administration of streptomycin and isoniazid in 
ultrasonic aerosols in the treatment of intrathoracic tuberculosis. Antibiotiki 1977; 
22: 469-471. 
 
71. Lovacheva OV, Erokhin VV, Chernichenko NV, Evgushchenko GV, Lepekha LN, 
Rozenberg OA. Results of use of surfactant in complex therapy of patients with 
destructive pulmonary tuberculosis. Probl Tuberk Bolezn Legk. 2006; 10: 12-17. 
 
72. Stoops JK, Arora R, Armitage L, Wanger A, Song L, Blackburn MR, Krueger GR, 
Risin SA, Certain surfactants show promise in the therapy of pulmonary 
tuberculosis. In Vivo. 2010; 24: 687-694. 
 
73. Larsson M. A surface phase model of the alveolar lining: ultra-structural analysis 
and in vivo applications. Thesis, Lund University, Malmö, 2002. 
 
74. Chimote G, Banerjee R. Evaluation of antitubercular drug-loaded surfactants as 
inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res 
A. 2009; 89: 281-292. 
 
75. Chimote G, Banerjee R. Effect of mycobacterial lipids on surface properties of 
Curosurf: Implications for lung surfactant dysfunction in tuberculosis. Respir 
Physiol Neurobiol 2008; 162: 73-79. 
 
 73 
 
76. R. Pandey, S. Sharma, G.K. Khuller, Liposome-based antitubercular drug 
therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents. 2004; 23: 
414–415. 
 
77. R. Pandey, A. Zahoor, S. Sharma, G.K. Khuller. Nanoparticle encapsulated 
antituberculardrugs as a potential oral drug delivery system against murine 
tuberculosis. Tuberculosis. 2003; 83: 373–378. 
 
78. Zaru M, Mourtas S, Klepetsanis P, Fadda A, Antimisiaris SG. Liposomes for drug 
delivery to the lungs by nebulization. Eur J Pharm Biopharm. 2007. 67: 655-666. 
 
79. Suarez S, Hickey AJ. Nebulizors-aerosol delivery: Drug properties affecting 
aerosol behaviour. Respiratory Care. 2000; 45: 652–666. 
 
80. Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. 
Pharm Res. 1990; 7: 1127–1133. 
 
81. K.M.G. Taylor, G. Taylor, I.W. Kellaway, J. Stevens. The stability of liposomes to 
nebulisation. Int J Pharm. 1990; 58: 57–61. 
 
82. Bridges PA, Taylor KMG. An investigation of some of the factors influencing the 
jet nebulisation of liposomes. Int J Pharm. 2000; 204: 69–79. 
 
83. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size 
and modelling of solute release profiles. Pharm Res. 1991; 8: 217–221. 
 74 
 
 
84. Niven RW, Carvajal TM, Schreier H. Nebulization of liposomes.III. The effects of 
operating conditions and local environment. Pharm Res. 1992; 9: 515–520. 
 
85. Eixarch H, Haltner-Ukomadu E, Beisswenger C, Bock U. Drug delivery to the 
lung: permeability and physicochemical characteristics of drugs as the basis for a 
pulmonary biopharmaceutical classification system (pBCS). J Epithel Biol 
Pharmacol. 2010; 3: 1-14. 
 
86. Washington N, Wilson CG, Washington C. Pulmonary drug delivery, in 
physiological pharmaceutics: Biological barriers to drug absorption. Wilson CG 
and Washington N, Eds, Ellis Horwood, UK, 1989:155-178. 
 
87. Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med. 
2006; 19: 47-53. 
 
88. LM of a cross section through a bronchiole in lung. Credit: BIOPHOTO 
ASSOCIATES/SCIENCE PHOTO LIBRARY; P590/0171 Rights Managed 
 
89. Normal bronchial epithelium. From the slide collection of the late Dr. Charles 
Kuhn, Digital Pathology, Browns Medical School. 
 
90. Smith EW. Ph.D. Thesis: Aspects of the transdermal permeation and analysis of 
Betamethasone 17β-Valerate, School of Pharmaceutical Sciences, Rhodes 
University, Grahamstown, South Africa, 1987. 
 75 
 
 
91. Viljoen I. M.Med.Sc. Thesis: The role of surfactant in, and a comparison of, the 
permeability of porcine and human epithelia to various chemical compounds, 
Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, 
South Africa, 2005. 
 
92. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral 
cavity. J Pharm Sci 1992; 81: 1-10. 
 
93. Regazzo D, Mollé D, Gabai G, Tomé D, Dupont D, Léonil J, Boutrou R. The (193-
209) 17-residues peptide of bovine β-casein is transported through Caco-2 
monolayer. Mol Nutr Food Res. 2010; 54: 1428-1435. 
 
94. Williams AC. Theoretical aspects of transdermal drug delivery. In: Williams AC, 
ed. Transdermal and topical drug delivery. London: Pharmaceutical Press. 2003: 
35-40. 
 
95. Barry BW, EL Eini DID. Influence of non-ionic surfactant on permeation of 
hydrocortisone, dexamethasone, testosterone and progesterone across cellulose 
acetate membrane. J Pharm Pharmacol. 1975; 34: 127-135. 
 
96. MacDonald RC, MacDonald RI, Menco B, Takeshita K, Subbarao NK, Hu L. 
Small-volume extrution apparatus for preparation of large, unilamellar vesicles. 
Biochimica et Biophysica Acta. 1991; 1061: 297-303 
 
 76 
 
97. Van Eyk A, Hons BSc. Thesis: Comparitive permeability of various chemical 
markers through human vaginal and buccal mucosa as well as porcine buccal 
and mouth floor mucosa. Division of Pharmacology, Faculty of Medicine and 
Health Sciences, Stellenbosch University, Tygerberg, South Africa, 2004 
 
98.  Motulsky, H.J. Prism 5 Statistics Guide, GraphPad Software Inc., San Diego, 
CA, USA, 2007 
 
99. Gregoire G, Dabsie F, Dieng-Sarr F, Akon B, Sharrock P. Solvent composition of 
one-step self-etch adhesives and dentine wettability. J Dent 2011; 39: 30–39. 
 
100. Manish G, Vimukta S. Targeted drug delivery system: A Review. Res J 
Chem.Sci. 2011; 1: 135-138 
 
101. Squier CA. The permeability of oral mucosa. Crit Rev Oral Biol Med. 1991; 2: 13-
32. 
 
102. Van der Bijl P, Penkler L, Van Eyk AD. Permeation of sumatriptan through 
human vaginal and buccal mucosa. Headache 2000; 40: 137-141.  
 
103. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, Ma JR. The transport 
barrier of epithelia: A comparative study on memebrane permeability and charge 
selectivity in the rabbit. Pharm Res. 1992; 8: 1029-1034. 
 
 77 
 
104. Mitchell HW, Fisher JT, Sparrow MP. The integrity of the epithelium is a major 
determinant of the responsiveness of the dog bronchial segment to mucosal 
provocation. Pulm Pharmacol. 1993; 4: 263-268. 
 
105. Chimote G, Banerjee R. Effect of antitubercular drugs on 
dipalmitoylphosphatidylcholine monolayers: Implications of drug loaded 
surfactants. Respir Physiol And Neurobiol. 2005; 145: 65-77. 
 
106. Karmakar S, Raghunathan VA, Mayor S. Phase behaviours of dipalmitoyl 
phosphatidylcholine (DPPC)-cholestrol memebranes. J Phys Condens Matter. 
2005; 17: S1177- S1182. 
 
107. Van der Bijl; Van Eyk AD. Comparative in vitro permeability of human vaginal, 
small intestinal and colonic mucosa. Int J Pharm. 2003; 261: 147-152. 
 
108. Neves P, Leite A, Rangal M, de Castro B, Gameira P. Influence of structural 
factors on the enhanced activity of moxifloxacin: A fluorescence and EPR 
spectroscopic study. Anal Bioanal Chem. 2007; 387: 154s3–1552. 
 
109. Van t’ Veen A, Mouton JW, Gommers D, Kluytmans JA, Dekkers P, Lachmanss 
B. Influence of pulmonary surfactant on in vitro bactericidal activities of 
amoxicillin, ceftazidime, and tobramycin. Antimicrob Agents Chemother. 1995; 
39: 329-333. 
 
 78 
 
110. Fresta M, Guccione S, Beccari AR, Furneri PM, Puglisi G. Combining molecular 
modelling with experimental methodologies: Mechanism of membrane 
permeation and accumulation of ofloxacin. Bioorg Med Chem. 2002; 10: 3871-
3889. 
 
  
 79 
 
8. ADDENDUM 
This study has been presented in part and in its entirety at national and 
international conferences. 
National conference: 45th Annual Congress 2011 of the SASBCP held in 
Durban, hosted by the University of Kwa-Zulu Natal, September 2011 
Abstract Title:  
The Influence of a Synthetic Lung Surfactant on the Permeability of 
Antimycobacterial drugs Through Porcine Lung Tissue. 
Lyné van Rensburg*, Johann van Zyl, Johan Smith+, Pieter van der Bijl and 
Heiner Seifart. 
Pharmacology, Department of Medicine, Faculty of Health Sciences, 
Stellenbosch University, Tygerberg, 7505, South Africa; +Department of 
Pediatrics, Tygerberg Children’s Hospital, Faculty of Health Sciences, 
Stellenbosch University 
International conference: 5th AFRICAN INTERNATIONAL CONGRESS OF 
BASIC AND CLINICAL PHARMACOLOGY, held at La Palm Royal beach 
hotel and hosted by University of Ghana, Accra, Ghana, July 2012 
Abstract Title:  
Studies of Liposomal Preparations of Anti-Tubercular drugs 
Lyné van Rensburg*, Johann van Zyl, Johan Smith+ and Heiner Seifart. 
Pharmacology, Department of Medicine, Faculty of Health Sciences, 
Stellenbosch University, Tygerberg, 7505, South Africa; +Department of 
 80 
 
Pediatrics, Tygerberg Children’s Hospital, Faculty of Health Sciences, 
Stellenbosch University   
 
